United States: What Say You, New York? Now That Federal Antitrust Regulators Have Approved CVS's Proposed Acquisition Of Aetna, Attention Turns To New York State

"I can stop the deal if it is reasonably necessary to protect New Yorkers."
Superintendent Maria Vullo of the New York State Department of Financial Services

During a public hearing in New York City on Thursday, October 18, 2018, New York State regulators, including Superintendent Maria Vullo of the New York State Department of Financial Services ("DFS"), threatened to block CVS Health's $69 billion merger with health insurer Aetna if (i) CVS would not agree to hold the line on rising insurance premiums for Aetna's member population in New York State (approximately 1.1 million New Yorkers across the State); and/or (ii) CVS Health refused to submit its CVS/Caremark pharmacy benefits manager ("PBM") business to State regulation.

As described in a widely cited New York Post article, "New York threatens to block $69B CVS-Aetna merger" by Josh Kosman (October 18, 2018), Ms. Vullo used the hearing to express DFS's concern that CVS Health, which had to borrow $40 billion to fund the $69 billion deal, could raise insurance premiums for millions of [New York State] residents as a result of the deal. Specifically, Ms. Vullo was quoted by Mr. Kosman as stating:

I can stop the deal if it is reasonably necessary to protect New Yorkers.... In [DFS's] view, there must be a clear enforceable commitment not to transfer the cost of paying back loans to policyholders. [Emphasis Added].

The Antitrust Division of the United States Department of Justice

As it has been widely reported, on Wednesday, October 10, 2018, Pharmacy chain CVS Health received conditional approval from the Antitrust Division of the United States Department of Justice (the "DOJ") for its $69 billion merger with health insurer Aetna. The condition? The deal was approved on condition that Aetna sell its reported $2.2 million Medicare Part D prescription drug plan ("PDP") business to WellCare Health Plans prior to, or concurrent with, the close of its transaction with CVS Health.

As described by the Antitrust Division in its October 10, 2018 public announcement ("Announcement") regarding its approval of the transaction subject to the PDP divestiture:

Aetna must divest its individual prescription drug plan business to WellCare and allow WellCare the opportunity to hire key employees who currently operate the business. Aetna must also assist WellCare in operating the business during the transition and in transferring the affected customers through a process regulated by the Centers for Medicare and Medicaid Services, an agency within the U.S. Department of Health and Human Services.

As reported in the Announcement, the DOJ concluded that if there were no divestiture of the Aetna PDP business, the anticipated consolidation in the PDP market resulting from the Aetna/CVS Health combination1 would, "cause anticompetitive effects, including increased prices, inferior customer service, and decreased innovation in 16 Medicare Part D regions covering 22 states." As a result, the DOJ maintains that without the required divestiture, "the loss of competition between CVS and Aetna would result in lower-quality services and increased costs for consumers, the federal government, and ultimately, taxpayers."

According to the DOJ and as reported in the Announcement, the required divestiture, "resolves competition concerns posed by this transaction and preserves competition in the sale of Medicare Part D prescription drug plans for individuals." Further, according to the DOJ, "[t]he divestitures . . . . allow for the creation of an integrated pharmacy and health benefits company that has the potential to generate benefits by improving the quality and lowering the costs of the healthcare services that American consumers can obtain."

United States of America v. CVS Health Corporation and Aetna Inc.

Simultaneous with the DOJ's release of the Announcement, the DOJ and five state attorneys general – from California, Florida, Hawaii, Mississippi, and Washington – filed a complaint in the U.S. District Court for the District of Columbia to enjoin CVS's proposed merger with Aetna. United States of America v. CVS Health Corporation and Aetna Inc., Civil Action No. 1:18-cv-02340. Accompanying the complaint was a proposed Final Judgement that includes the terms of the Plaintiffs' willingness to approve the transaction, such terms including the divestiture terms described above. Although the proposed Final Judgement must still go through a 60-day comment period, it is expected that the U.S. District Court will ultimately approve the transaction.

New York State DFS and its Efforts to Regulate and Oversee PBMs in New York State

Since New York State and other states were not parties to the litigation challenging the CVS/Aetna deal, the terms of their individual approvals were/are state-specific matters. At the time of the complaint's filing, Connecticut and New York were presenting the greatest challenges to Aetna's and CVS Health's efforts to obtain all requisite approvals to move forward with the merger transaction. However, on October 17, 2018, the Connecticut Insurance Department approved the CVS Health/Aetna merger transaction subject to the same requirements set forth in the Final Settlement issued by the DOJ and the five state plaintiff group on October 10, 2018 – i.e., Aetna must complete the sale of its entire standalone PDP business to a subsidiary of WellCare Health Plans.

As a result of Connecticut's approval action on October 17, 2018, New York State found itself on October 18, 2018 – the day the New York State DFS held its public hearing in Manhattan to discuss the transaction and to receive public input regarding the transaction (See, below) – to be the most significant hurdle standing in between Aetna and CVS Health and their mutual desire to complete their merger transaction by December 31, 2018.

A Public Hearing to be Remembered.

As reported in in the New York Post (See, above) and by Crain's New York Business on October 19, 2018, "State considers blocking parts of CVS-Aetna merger," in a public hearing held on October 18, 2018, Ms. Vullo said that the DFS might block CVS's merger with Aetna's New York unit. She called U.S. approval of the overall deal "myopic" and repeatedly asked CVS and Aetna representatives for written evidence that they would deliver on promises to lower prices.

As explained by Ms. Vullo in her opening statement, the DFS believes there are "significant risks" in the CVS/Aetna transaction because "large corporate for-profit conglomerates do not have a good history of serving the public above their shareholders" and that the benefits advocated by the transaction are just "puffery." The DFS solution? "Regulators, including DFS, must have oversight going forward." Currently, although DFS has regulatory authority over health plans in New York, it does not have oversight over Pharmacy Benefit Managers ("PBMs") such as CVS Caremark. According to Ms. Vullo, PBMs are a "cog in the wheel for profit-making" that ultimately redounds to the detriment of consumers.

This is not a new position. As explained by Ms. Vullo, DFS proposed legislation for the licensing and direct supervision of PBMs two years ago. Although DFS's efforts did not bear fruit at the time, Ms. Vullo said that the DFS will continue to advocate for the licensing of PBMs despite, what Ms. Vullo characterized as PBM opposition to "transparency and regulation."

Finally, as reported by the New York Post in the article cited at the outset of this wrighting, "With her glasses on the tip of her nose, Ms. Vullo asked CVS lawyer Elizabeth Ferguson in a booming voice: 'Will you vocally support the bill [granting DFS oversight over PBMs]?' In response, Ms. Ferguson replied, 'We would not oppose it....'."

Ultimately, it appears that regulatory approval in New York may not come without conceding regulatory oversight of PBMs to DFS.


1 Without the divestiture, it has been reported that the combined companies would have been responsible for 32% of PDP enrollment based upon 2018 enrollment data. As reported by Richard M. Scheffler in his paper, "The Impact of CVS's Acquisition of Aetna on Medicare Part D Stand-Alone Prescription Drug Plan Market Concentration," dated May 29, 2018, the then current data showed that five PDP sponsors accounted for 83% of PDP enrollment in 2018: CVS Health (24%, 6 million enrollees), UnitedHealth (21%, 5.3 million enrollees), Humana (20%, 4.9 million enrollees), Express Scripts (10%, 2.4 million enrollees), and Aetna (9%, 2.1 million enrollees).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Oct 2019, Seminar, Los Angeles, United States

Please join us for Sheppard Mullin's Labor & Employment Law Update & Happy Hour Seminar Series.

16 Oct 2019, Webinar, Los Angeles, United States

This activity has been approved for Minimum 1 Continuing Legal Education credit by the State Bar of California.

16 Oct 2019, Conference, New York, United States

Black women often are misidentified as holding a position other than the attorney role, whether it be the secretary, paralegal, court reporter or even stenographer.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions